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Patient-centered careBackground: The capacity of TAVI-programs and numbers of sites performing TAVI has rapidly increased. This ne-
cessitated the initiation of the Rotterdam TAVI Care & Cure Program, aiming to improve patient-centered care
during the TAVI pathway.
Methods: Consenting patients with severe aortic stenosis and an indication for TAVI will be included. The TAVI
Care& Cure programwill facilitate prognostic contributions to improve outcomes, patient satisfaction andquality
of life in patients with valvular heart disease who are treated with a transcatheter aortic valve implantation in
collaboration with the departments of cardiology, cardio-thoracic surgery, anesthesiology and geriatrics.
Conclusion:With a single center observational registry, we aim to assess the TAVI patient clinical pathway, focus-
ing on pre, peri and post interventional variables including functional status and HRQoL. We will evaluate the
patient's complexity by applying an extended multidisciplinary approach, which includes a systematic applica-
tion of geriatric assessments of frailty and cognitive function.
© 2019 Published by Elsevier B.V.1. Introduction
Transcatheter aortic valve implantation (TAVI) is increasingly being
utilized to treat patients with severe aortic stenosis (AS) who are con-
sidered at intermediate or high risk for surgical aortic valve replacement
(SAVR). TAVI, a less-invasive therapeutic option, is expected to become
the standard treatment in all patients with aortic stenosis but will pre-
dominantly be applied in an increasingly elderly population given the
increase of this population group [1–3]. Elderly patients differ from
younger patients in terms of frailty (a state of reduced physical, cogni-
tive and social functioning, resulting in a reduction of reserve capacity
for dealing with stressors) [4] due to a higher prevalence of medical
co-morbidities leading to a more pronounced reduction in functional
status and health related quality of life (HRQoL).
Despite improvements in immediate outcomes (i.e. safety) as a re-
sult of enhanced operator experience, progress in device technology
and post-operative care, a proportion of patients do not survive beyond
oneyear or at best show limited or no improvement inHRQoL after TAVI
[1,2,5]. This is particularly evident for the elderly patient (N80 years) ne-
cessitating a more delicate and balanced decision-making (risk/benefitCE Rotterdam, the Netherlands.
Jaegere).assessment) including the understanding of other factors that deter-
mine immediate and above all long-term outcomes [6–9]. In this con-
text frailty is of significance, as it is associated with chronic diseases
and increased age, negatively influencing morbidity and mortality
after TAVI. Importantly, through advocacy of the European Society of
Cardiology, frailty has now been incorporated into the decision-
making process [10].
Also other components such as mental status, nutrition and socio-
economic status,which are not only relevant for the elderly patient pop-
ulation, will be taken into account. This in combination with a higher
prevalence of medical antecedents and co-morbidities renders formu-
lating treatment strategies in the elderly complex and requires further
analysis into whether specific geriatric interventions before and/or
after TAVI may improve immediate and long-term outcome after TAVI
[10]. For this reason, a dedicated TAVI program entitled TAVI Care &
Cure was initiated in our institution of which the details are herein fur-
ther described.
2. Study design
The TAVI Care & Cure study is a prospective single-centermultidisci-
plinary observational cohort study in which a comprehensive set of
predefined cardiovascular and non-cardiovascular variables are
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interventional patient pathway whilst “Cure” entails the interventional
treatment phase. Inclusion criteria are all consecutive patients with se-
vere symptomatic AS, not considered for conventional open heart valve
surgery techniques, who are deemed eligible for TAVI by a multi-
disciplinary heart valve team. Furthermore aspects as technical suitabil-
ity, frailty and co-morbidities are considered in the decision making
process. Patients will be excluded if co-morbidities and/or their general
condition is not expected to improve their quality of life and/or a sur-
vival expectation of b1 year. Candidates who are not eligible for TAVI
will be excluded from this study. Inherent in this observation cohort
study, no control group will be used.
Patients older than 70 years with an indication for aortic valve re-
placement therapy (outpatient cardiology assessment) are referred for
comprehensive geriatric assessment (CGA)which consists of hetero, so-
cial and functional anamnesis,medication reviewand frailty assessment
to determine deficits in geriatric domains by using validated frailty as-
sessment tools [11].
The primary objective of the TAVI Care & Cure program is to improve
the treatment and care of patients with aortic stenosis undergoing a
TAVI following a novel, dedicated clinical TAVI-pathway. This pathway
encompasses pre-admission assessments, diagnostic work-ups, heart
team consultations, interventional treatment and lastly outpatient
follow-up. Collected data will provide additional information
concerning the understanding of the safety and device performance
and also how to treat patients in a real world setting including HRQoL.
Secondary objectives are to access the role of frailty in this popula-
tion and to quantify patient characteristics and criteria for possible
early discharge eligibility.
For these purposes immediate outcomes and clinical endpoints (i.e.
safety, life-threatening or major bleeding, major vascular complications,
in-hospital major stroke, in-hospital acute kidney injury, and 30-daymor-
tality) are assessed using the Valve Academic Research Consortiumcriteria
(VARC-2 criteria) [12] in addition to the occurrence of non-cardiovascular











12‑Lead ECG X X X
NYHA & CCS class X
VARC-2 definitions X
Trans thoracic echo X X X
Multi slice computer tomography X
Coronary angiography X
Informed consent X
Screening on allergic for contrast medium X
Pre-hydration prophylaxes X
Endocarditis prophylaxes (if indicated
lifelong)
X X
Anti-thrombotic prophylaxes X X X
Telemonitoring
Thorax X-ray X
HR-QoL: EQ-5D & VAS X
Temporary pacemaker If indicated R
Urinary catheter If indicated
Observation⁎⁎ X
Medication X
Mobilization/ambulation 4–6 h post
procedure, revalidation (If indicated
physiotherapy)
If PPM/ICD implantation PM-control
ECG: electrocardiogram; NYHA class: New York Heart Association functional classification; CCS
initions: HR-QoL: health related quality of life; EQ-5D-5L: EuroQoL quality of life scale; VAS: vis
tor; e-GFR: estimated glomerular filtration rate; CRP: C-reactive protein; NT-pro BNP: pro b-ty
⁎ Blood: e-GFR, cardiac enzymes, ureum, creatinine, CRP, NT-pro BNP, hemoglobin.
⁎⁎ Active clotting time (ACT), heamodynamics, arrhythmias, conduction-disturbances, bleediEfficacy of treatment is assessed by monitoring survival freedom
from major adverse cerebro-cardiovascular events, functional class
and HrQoL at 30 days, one, three, and five year. Assessment of utility
or futility of treatment will be based upon analysis of long-term out-
comes such as survival, survival free from stroke, reduction or loss in/
of ADL. These analyses will help to formulate improvements in treat-
ment allocation, patient preparation and postoperative care.
The Medical Ethics Committee of the Erasmus Medical Center
reviewed the study (MEC-2014-277) and since this study was not sub-
jected to the Dutch Medical Research Involving Human Subjects Act no
approval was required. The study will be performed according to the
Helsinki Declaration and all patients must consent for participation.
3. The TAVI pathway
3.1. Diagnostic assessments
Cardiac and geriatric examinations and assessments will be per-
formed and include medical history and physical assessments, 12‑lead
ECG, laboratory results, thorax X-rays, diagnostic coronary angiogram,
multi–slice computed tomography (MSCT), trans-thoracic and/or
trans esophageal echocardiography and quality of life measurements.
The following geriatric domains will be assessed: cognition and nutri-
tional status, (instrumental) activity of daily living, mobility andmuscle
loss (see Table 1b for used instruments) [13–18].
3.2. Patient selection— multidisciplinary heart valve team meeting
The TAVI Care & Cure program has been developed and initiated
with the collaboration of the departments of cardiology, cardio-
thoracic surgery, anesthesiology and geriatrics.
Using awell-designedmultidisciplinary approachwith collaborative
input of diverse specialists of the heart valve team, the treatment deci-
sion process is not only thoroughly discussed leading to an improved
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X X X X X X
X X
X X X X X
class: angina grading scale; VARC-2 definitions: valve academic research consortium def-
ual analogue scale; PPM: permanent pacemaker; ICD: implantable cardioverter-defibrilla-
pe natriuretic peptide.





















Functional anamnesis⁎ X X
Social anamnesis⁎⁎ X X
Cognitive function X X
HR-QoL: RAND SF-36 X X
Mobility: time up-and go
test
X




Handgrip strength test X
Consult geriatrician X X X If indicated
No geriatric involvement X X
Delirium-observation X X X If indicated
HR-QoL: health related quality of life; RAND-36: 36-item short form health survey; MSSE: mini-mental state examination; Katz: index of independence in activities of daily living; IADL
(Lawton & Brody): the Lawton Instrumental Activities of Daily Living scale; MUST: Malnutrition Universal Screening Tool.
⁎ Functional anamnesis: ADL (KATZ), iADL (Lawton & Brody), independence, fallrisk, nutritional status (MUST) and incontinence.
⁎⁎ )Social anamnesis: married, divorced, widowed, (no) children, life events, care, living environment.
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For instance, prevention of post procedural complications are deliber-
ated in terms of either physical function such as stroke, vascular compli-
cations, renal failure, paravalvular leak and conduction disorders and in
terms of cognitive function such as delirium. The treatment decision, in-
corporating diagnosis, complexity and multiple co-morbidities, be it for
optimum medical therapy, TAVI or SAVR, are taken at the weekly mul-
tidisciplinary heart valve team meeting (Fig. 1). Importantly, the use
of a multidisciplinary heart valve team for the management of patients
with valvular heart diseases is strongly recommended (Class I, level
C) in the current ESC guidelines [10].
All patients accepted, for either a TAVI or SAVR procedure, are sched-
uled for a preoperative visit at the outpatient clinic anesthesiology in
order to complete the pre-procedural diagnostic workup.
3.3. Intervention procedure
The TAVI-procedure is performed under local anesthesia and antibi-
otic prophylaxis [10] in a cathlab suite with full facilities for general an-
esthesia, echocardiography and cardiopulmonary support if needed.
Any commercially available trans catheter heart valve (THV) can be
used. In our institution the balloon expandable Edwards Sapien 3
valve (Edwards Lifesciences Corp., Irvine, California), the self-
expandable Acurate neo valve (Boston Scientific, Marlborough, Massa-
chusetts) and the self-expandable Evolute R-and Pro valve (Medtronic
Inc. Minneapolis, Minnesota) are currently used. Vascular access and
pre-closure is performed under echo-guidance. After vascular access,
all patients receive cerebral protection using a cerebral protection filter
unless the anatomy of the brachiocephalic and/or left common carotid
artery precludes its use or is contra-indicated [19,20]. The valve size se-
lection is based upon the screeningMSCTof the aortic root and the valve
implantation is performed without pre-balloon valvuloplasty (direct
valve implantation). Contrast angiography and Trans Thoracic Echocar-
diography are used for implantation guidance and post implantation
evaluation. In the case of a high degree atrioventricular (AV) block dur-
ing the procedure a temporary pacemaker (TPM) is left in situ up to 24 h
and removed when clinically justified. Hemostasis is achieved by using
either a plug-or suture based vessel closure device followed by selective
arterial angiography to assess for hemostasis [21,22].
3.4. Post procedural management/discharge
After the TAVI procedure, patients aremonitored for at least 2–4 h at
the Cardiac Care Unit. When the patient is considered to behemodynamic stable and in the absence of complications, the patient
is then transferred to the Medium Care Unit for further observation
and mobilization until hospital discharge. Furthermore access site as-
sessment for potential late bleeding and also telemetricmonitoring sup-
plementedwith regular ECG's for potential conduction abnormalities up
to 72 h post intervention is mandatory. Moreover in terms of early rec-
ognition of delirium the geriatrician will evaluate daily the patient
(Table 1b).
The expected discharge is between 3 and 7 days post procedure.
Post-TAVI anti-thrombotic therapy consists of Aspirin (lifelong) and
Thienopyridine (for threemonths). In patients indicated for oral antico-
agulant therapy, Clopidogrel for three months will be administered.
In addition to a one-month follow-up visit, further follow-up is
scheduled at one, three and five year's post-TAVI (Table 1b). In the con-
text of evaluating changes for the degree of AS related symptoms and
functional status, patients are asked to complete a generic health status
questionnaire (i.e. EuroQOL five dimensions (EQ-5D)) including the vi-
sual analogue scale (EQ-VAS) at baseline, twelvemonths, three and five
years [23].
3.5. Patient safety and quality of care
The weekly TAVI meeting is attended by the TAVI interventionalist,
accompanied by a team of dedicated interventional cardiology fellows
involved in the TAVI program and the TAVI nurse coordinator. During
this meeting in-hospital post-TAVI patients are discussed and reviewed
for post-procedure in-hospital care, eventual complications, length of
stay and discharge preparation. Furthermore patients undergoing a
planned TAVI procedure in the following week are again assessed ac-
cording to an adjusted format (i.e. medical history, comorbidities,
established risk scores, status of the conduction-system, echo-
outcomes, status of the coronary anatomy, use of embolic protection,
access, closure and possible inclusion in a study).
4. Data management
All demographic, clinical complications and related data such as lab-
oratory assays, ECG and echocardiographic data will be collected during
the outpatient visits at both the cardiac and geriatric departments. In
addition a concise set of variables collected during TAVI are entered
into a dedicated database.
Captured data is entered on a structural basis and a collaborative
manner in the dedicated TAVI database by three groups of participants;
a medical student team accompanying the TAVI-cardiologists during
Fig. 1. The heart team multidisciplinary decision-making process.
39M.J.A.G. De Ronde-Tillmans et al. / International Journal of Cardiology 302 (2020) 36–41the outpatient clinic, the fellows involved in the TAVI program and by
the geriatrician team members.
The dedicated database is hosted on an internal server. It is not ac-
cessible from an external point of contact and it features real time
user tracking / logging and facilitates simultaneous /multiple user
interaction.4.1. TAVI nurse coordinator
The success of a multi-disciplinary team approach with special at-
tention to patient care is dependent on the organizational skills of a cen-
tral individual (Fig. 2). The TAVI-nurse coordinator informs at the pre-
admission phase the patient and his/her relatives regarding the details
of the procedure. Also the TAVI nurse oversees the patient's in-
hospital, discharge and follow-up phases. Knowledge of the patient's
pathway, therapy treatment, dischargemanagement and social support
is a key factor in the TAVI Care & Cure program. In addition offering a
point of contact to the patient, both in-hospital and post discharge,enhances the patients well-being, benefiting a thorough preparation
for, and information about the patient's treatment.
5. Discussion
Aortic stenosis is the most common valve disease in elderly adults
with a growing prevalence due to the aging population [3]. TAVI, cur-
rently performed in over 70 countries [24], has evolved as a less inva-
sive, safe and effective alternative treatment of patients with severe
symptomatic AS who are at high or prohibitive risk for surgical aortic
valve replacement [2].
Evidence from randomized clinical trials comparing outcomes of
SAVR versus TAVI has led to a broadening of indications for TAVI with
an expansion from the initial high-risk surgical group onto currently
an intermediate and low risk population [1,25,26] resulting in a expo-
nentially volume growth of TAVI worldwide. A shared and balanced de-
cision making strategy by the Heart Valve Team includes an
individualized approach of patient specific risk assessment and the
use of additional outcome measures reflecting patient related safety
and clinical endpoints (i.e. 30-day mortality, VARC-2 variables) [10,12].
Since the first TAVI was performed in 2002 [27], there has been a
major evolution of developments and transformation of CE-marked
TAVI systems. Furthermore technical advancements in the current de-
vice technology have led to amongst others i.e. lower profiles of the de-
livery systems, retrievable and repositionable features as also
improvements in designs leading to a reduction in paravalvular leakage.
Themost preferred access route is the trans femoral (TF) route. Alterna-
tives are the trans-apical, trans-subclavian and direct aortic route. In ad-
dition, the operator experience has intuitively increased, reflecting in a
more specified case selection and procedural strategy leading to im-
proved reduction of peri-procedural events and clinical outcomes post
TAVI. The Dutch Guidelines for Competencies for Transcatheter Heart
Valve Intervention stated that an institution must achieve at least 75
TAVI-procedures per year to be considered “established” within three
years of inception of the program [28].
The afore mentioned developments have led to the establishment of
this TAVI Care & Cure program in our center, initiated to collect data
from all TAVI patients. Further formalizing and structuring this TAVI
program by utilizing the captured data, enables real-time monitoring
and improvement of the quality of care, to present transparent reports
of site performance on a regular basis providing additional information
on i.e. in-hospital and 30-day mortality, vascular complications, bleed-
ing, conductions disturbances and disabling stroke, as well as frailty as
predictor for mortality (30-day and 1 year) and HRQoL post TAVI. The
advantages of the implementation of TAVI Care & Cure is the uniformity
of data collection, data integrity and analysis, all stored in one dedicated
database.
A comprehensive tailored TAVI dataset is nowmandatorily, annually
reported to the national health inspector via a national registry plat-
form, the Dutch Heart Registry (NHR, Nederlandse Hartregistratie).
The NHR is a major cardiovascular quality-of-care registry and aims to
monitor and improve quality of care of heart disease for the individual
patient by collecting and analyzing patient data, reporting relevant out-
come indicators in annually public accessible reports. Additionally an
independent academic Clinical Events Committee (CEC) will evaluate
regularly adverse events according to international guidelines and defi-
nitions (VARC-2, Bleeding Academic Research Consortium (BARC), the
ESC Myocardial Infarction Definitions) [29–31].
In terms of specific research questions, two distinct areas will be ex-
plored in detail. Firstly as there is a growing interest in the assessment of
frailty, which is associated with increasedmorbidity andmortality after
SAVR and TAVI [8]. Frailty has been added in complement to the con-
ventional risk scores (Society of Thoracic Surgeons (STS) score and
European System for Cardiac Operative Risk Evaluation (EuroSCORE-
II)) in the TAVI Care & Cure program. To incorporate frailty in terms of
functionality, HRQoL and other existing disabilities in the patient
Fig. 2. Contributors in the TAVI-pathway.
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between those patients who will benefit from TAVI and those who
will not. Currently there is debate ongoing concerning the need to de-
velop a dedicated TAVI orientated quality of life questionnaire. The
TAVI Care & Cure data may also contribute to this debate.
Secondly improvements in risk-stratification andpatient selection in
conjunction with a shift to lower-risk patients coupled with the stan-
dardization of TAVI-procedures have led to an early discharge program
in our institution. This program simplifies the TAVI-procedure, de-
creases its duration and reduces procedural related complications by in-
cluding a fully percutaneous trans femoral access site entry and closure,
performed under local anesthesia and early mobilization [32,33].
There is currently no consensus over the definition ‘early discharge’.
A recent meta-analysis of 8 observational studies including 1775 pa-
tients, evaluating early discharge to 30-day mortality, suggests that
early discharge by day 3 after TAVI in selected patients who underwent
an uncomplicated TAVI is safe in terms of mortality, discharge to 30-day
or need for a permanent pacemaker after discharge [34]. Incorporating a
simplistic/minimalistic approach into clinical practice starts with
performing a pre-procedure screening of patient's functional and cogni-
tive status and suitability for an early discharge pathway. That includes
a more refined selection of suitable valve type based upon integrating
the pre-procedural ECG interpretations including P-R interval, QRS du-
ration and the electrical axis. It's important to inform the patient and
his/her social network that an early discharge can be anticipated if the
post-procedural period is uneventful to ensure that one patient's social
support and network is prepared for a potential early discharge.
In essence, the ambition of this dedicated TAVI Care & Cure program
is to gain more insights into existing and novel variables.
6. Conclusion
With a single center observational registry, we aim to assess the
TAVI patient clinical pathway, focusing on pre, peri and post interven-
tional variables including functional status andHRQoL.Wewill evaluate
the patient's complexity by applying an extended multidisciplinary ap-
proach, which includes a systematic application of geriatric assessments
of frailty and cognitive function.Authors contributions
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